[PAL-1 5G/4G polymorphism in patients with systemic lupus erythematosus]
Akusherstvo I Ginekologiia
|February 14, 2015
Summary
The PAI-1 4G/5G gene polymorphism does not impact pregnancy outcomes in women with systemic lupus erythematosus (SLE) who do not have secondary antiphospholipid syndrome (APS). This finding clarifies the role of thrombophilia in SLE patients.
Area of Science:
- Rheumatology and Immunology
- Reproductive Medicine
- Genetics
Context:
- Systemic lupus erythematosus (SLE) is a significant autoimmune disease predominantly affecting women, often leading to obstetric complications.
- Inherited thrombophilias are known risk factors for pregnancy loss, but their specific role in SLE patients, particularly those without secondary antiphospholipid syndrome (APS), remains unclear.
Purpose:
- To investigate the association between the PAI-1 5G/4G gene polymorphism and reproductive outcomes in women with SLE.
- To determine if PAI-1 5G/4G polymorphism influences disease activity or obstetric complications in SLE patients without secondary APS.
Summary:
- A study genotyped 103 SLE patients and 69 healthy controls for the PAI-1 5G/4G polymorphism (rs1799889).
- No significant differences in genotype prevalence were found between SLE patients and controls.
- Among SLE patients without secondary APS, PAI-1 5G/4G genotype did not correlate with pregnancy frequency, spontaneous abortions, or live birth rates.
- The polymorphism was not significantly related to SLE ACR criteria or disease activity but showed a potential influence on platelet count.
Impact:
- This research clarifies that PAI-1 4G/5G polymorphism is not a risk factor for adverse reproductive outcomes in SLE patients lacking secondary APS.
- Findings contribute to understanding the genetic factors influencing pregnancy in autoimmune diseases.
- The study highlights a potential link between PAI-1 polymorphism and platelet count in SLE patients, warranting further investigation.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
12.4K
12:04The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
19.1K
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
166
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
166
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:27Principles of Pharmacogenetics: Types of Genetic Variants
119
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
01:05Single Nucleotide Polymorphisms-SNPs
20.3K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.3K
01:29Pharmacogenomics: Identification of New Drug Targets
98
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98